TU Delft and UMC Utrecht spinout MILabs has been purchased by Rigaku Corporation, which plans to use its medical imaging technology in drug development.
Scientific instrument producer Rigaku Corporation has paid an undisclosed amount to acquire MILabs, a Netherlands-based medical scanning system developer spun out of University Medical Center Utrecht and TU Delft.
MILabs has created a multimodal system that incorporates X-ray computed tomography (CT), positron emission tomography (PET), single-photon emission computed tomography (SPECT) and optical imaging capabilities.
Frederik Beekman, head of TU Delft’s Biomedical Imaging department, is the founder, chief executive and chief scientific officer of the company.
Thuja Capital Healthcare Fund II and Value Creation Capital had combined to provide an undisclosed amount of funding for MILabs in 2016. Rigaku said it bought the spinout for the potential of its technology in the development of new therapeutics.
Paul Althuis, director of TU Delft’s investment arm, Delft Enterprises, said: “TU Delft not only conducts ground-breaking research, but wants to make an impact for a better society as well.
…
